Gilgamesh Pharmaceuticals

Gilgamesh Pharmaceuticals is a private, clinical-stage biotech leveraging a proprietary AI-powered discovery platform to develop next-generation, non-hallucinogenic neuroplastogens and other novel compounds for major depressive disorder, anxiety, and opioid use disorder. The company has advanced multiple candidates into Phase 2 trials, secured a significant collaboration with AbbVie, and is backed by notable investors like Y Combinator and Prime Movers Lab. With a seasoned leadership team from top biopharma and academia, Gilgamesh is positioned at the forefront of the emerging precision psychiatry sector, aiming to address the global mental health crisis with safer, more effective therapies.

Proprietary AI-powered discovery and translational platform utilizing complex behavioral assessment, advanced electrophysiology, molecular neuroplasticity measures, and machine learning to optimize novel psychoactive drug candidates.

Gilgamesh competes in the rapidly growing neuroplastogen and psychedelic-inspired medicine sector against public companies like Compass Pathways (COMP360), Cybin (CYB003), and ATAI Life Sciences, as well as numerous private biotechs. Its key differentiation lies in its AI-driven platform to engineer non-hallucinogenic compounds and its strategic partnership with a major pharma player, AbbVie.